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Abstract 
 
ES-62 is a protein secreted by the parasitic worm Acanthocheilonema viteae that is anti-
inflammatory by virtue of covalently attached phosphorylcholine. Previously we have 
reported that drug-like Small Molecule Analogues (SMAs) of its phosphorylcholine moiety 
can mimic ES-62 in protecting against disease development in certain mouse models of 
autoimmune and allergic conditions, due to them causing partial degradation of the TLR/IL-
1R adaptor MyD88. We have now taken a molecular modelling approach to investigating the 
mechanism underlying this effect and this predicts that the SMAs interact directly with the 
MyD88 TIR domain. Further support for this is provided by assay of LPS-induced MyD88/ 
NF-NB-driven secreted alkaline phosphatase (SEAP) reporter activity in commercially-
available stably transfected (TLR4-MD2-NF-NB-SEAP) HEK293 cells, as SMA12b-
mediated inhibition of such SEAP activity is blocked by its pre-incubation with recombinant 
MyD88-TIR domain. Direct binding of SMA12b to the TIR domain is also shown to inhibit 
homo-dimerization of the adaptor, an event that can explain the observed degradation of the 
adaptor and inhibition of subsequent downstream signalling. Thus, these new data identify 
initial events by which drug-like ES-62 SMAs, which we also demonstrate are able to inhibit 
cytokine production by human cells, KRPHRVWDWLFDOO\PDLQWDLQ³VDIH´OHYHOVRI0\'
signalling.  
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Introduction 
ES-62, a secreted product of the parasitic filarial nematode, Acanthocheilonema viteae1, has 
been shown in a number of studies to be a highly effective immunomodulatory agent. 
Specifically, this molecule can interfere with the pro-inflammatory responses of various 
immune system cells including B cells, dendritic cells (DCs), macrophages and mast cells. 
[reviewed2]. Such immunomodulatory properties dictate that ES-62 has protective effects in a 
number of mouse models of inflammatory disease, in particular collagen-induced arthritis 
(CIA)3-6, ovalbumin-induced airway-hyper-responsiveness (OAH)7-9, oxazolone-induced skin 
hypersensitivity (OSH)7, the MRL/Lpr model of systemic lupus erythematosus (SLE)10 and 
the Gld.ApoE-/- model of accelerated atherosclerosis in SLE11. In spite of this, ES-62 per se 
does not directly have potential as a therapy, being a protein whose biological activity is 
dependent on post-translational attachment of phosphorylcholine moieties to an N±type 
glycan by a mechanism that is not fully characterised [reviewed12]. For this reason, a library 
of small molecule analogues (SMAs) based upon the active phosphorylcholine moiety but 
containing chemically stable substitutes for the phosphate ester, principally sulfonamides and 
sulfones, was designed, and evaluated by measuring ability to modify the cytokine output 
profile of stimulated macrophages13, DCs14  and mast cells15. Some of the sulfones were 
found to impact on cytokine output profiles in a manner similar to that of ES-62 and two in 
particular, 11a (also known as S3) and 12b (also known as S5)13, were selected for further 
evaluation. These have since been shown to be safe and effective when tested in CIA13,16, 
OAH 15 and other airway hypersensitivity models employing clinically relevant allergens17, 
the MRL/Lpr mouse model of SLE18 and OSH19. Of note, the two SMAs acted at low doses 
(50 µg/kg), showed both prophylactic and curative effects, and have recently been found to 
be protective in CIA when administered as DC therapy14. By contrast, the sulfonamides 
 4 
generally did not mimic the immunomodulatory effects of ES-62. Indeed, a typical example, 
19o, which was previously shown to have negligible effects on pro-inflammatory cytokine 
release from macrophages13 and not to protect against disease development in the MRL/Lpr 
SLE model18, was investigated further in the current study as a potential negative control. 
The structures of the 3 SMAs are shown in Figure 1. 
 
Although there may be additional targets for the SMAs, it is likely that the primary target, as 
with ES-62, is MyD884,10,20, a 31 ± 33 kDa adaptor protein consisting of a so-called N-
terminal death domain and a C-terminal Toll/interleukin-1 receptor (TLR/IL-1R; TIR) 
domain separated by a short linker region, which acts as an anchor, recruiting signal 
transducers to TLRs/IL-1R and also other receptors including that for IFN-J21-26. Consistent 
with this, both 11a and 12b reduce levels of this important adaptor molecule in bone marrow-
derived macrophages13,16 and also kidney cells18. Imbalance of MyD88 function in the 
immune system can result in excessive stimulation of inflammatory signalling, leading to a 
wide range of syndromes and diseases, including those that ES-62 has been shown able to 
modulate in model systems. Because of its important role in signal transduction, MyD88 and 
its complexes have been identified as potential drug targets27,28 particularly, in reducing the 
inflammatory impact of sepsis following bacterial infection29-31, autoimmune connective 
tissue diseases32, and lymphomas27. In addition to peptide inhibitors of MyD88 dimerisation, 
small molecule inhibitors ³7-VHULHV´LQKLELWRUVhave been investigated using virtual 
screening of a compound library containing 5 million members via binding to a protein-
protein dimeric docking model of the TIR-domain of MyD8833. From a first generation hit 
compound (T5910047; Figure 2 LHS), others were identified from the PubMed database with 
more drug like properties (Centre and RHS; Figure 2) and the most active compound 
(T6167923; RHS Figure 2) evaluated in a range of immunological and biochemical assays 
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relevant to MyD88 function, which indicated that it exhibited its anti-inflammatory actions 
via inhibition of MyD88 homodimerisation33. Compound T6167923 was also found to have 
therapeutic efficacy in protecting mice from staphylococcal enterotoxin B (SEB)-induced 
septic shock following administration of a single dose33. The similarity of these T-series 
compounds in terms of immunological profile (reducing the release of pro-inflammatory 
cytokines from stimulated cells) with that of the SMAs of ES-62 together with a number of 
common structural features with the SMA library suggested that it was possible that the 
active SMAs, 11a and 12b, by binding to the same or nearby sites on the MyD88 surface, 
might also disrupt its dimerisation. 7KHµDFWLYH¶60$V11a and 12b, and the µLQDFWLYH¶60$
19o were therefore examined initially as ligands for MyD88 in silico. Subsequently their 
effects on MyD88 protein complex formation and its downstream consequences were 
evaluated.  
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Results  
Molecular modelling reveals potential binding sites for ES-62 SMAs in the MyD88 TIR 
domain 
The similarity between the SMAs and the T-series compounds was first evaluated formally 
using the previously described molecular modelling methods33. As a reference, Figure 3a 
shows the docking of molecule T5910047 in two different binding poses and the overall top-
UDQNHGVFRUHVIURP9LQDǻG and the computed PC-Score.  Because T5910047 was derived 
from in silico screening of roughly 5 million compounds without ligand-binding optimization 
or refinement and showed an inhibition level as a minimal threshold for compound selection, 
the T5910047 score is used as a benchmark for assessing the three ES-62 SMA compounds.  
The two binding poses of T5910047 illustrated in Figure 3a are nearly indistinguishable in 
WHUPVRIVFRULQJDQGDUHJLYHQE\9LQDǻG  ޤNFDOPRODQGPC-Score  ޤNFDOPRO
When enrichment of compound selection is taken into consideration based on T591004733, 
the top-ranked 2nd-JHQHUDWLRQFRPSRXQG7GRFNLQJSRVHQRWVKRZQ\LHOGHGDǻG 
 ޤNFDOPRODQGPC-Score  ޤNFDOPRO   Concurrence in predicted binding regions for 
T5910047 and T6167923 is observed at site-1 and site-2 of MyD88, while site-3 is less 
favourable in terms of docking populations among the generated ensemble.   
While in general docking scoring functions are imperfect in detecting optimal conformational 
poses, the scoring method of PC-Score appears to offer the better guidance on ranking 
potential interactions for small molecules with MyD88.  This is buttressed by the negligible 
statistical variance in PC-Score values among the top-ranked 25 binding poses for a selected 
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molecule and as such, the differences in aggregate values can be applied to distinguish 
compounds.  For the three SMAs, docking successfully sampled favourable binding modes 
on the MyD88 model, although unlike T5910047 and T6167923, docking populated the three 
binding sites (Figure 3b, e and g).  There were some similarities observed at functional group 
level between the SMAs and T-series compounds. Figure 3d shows the docking of 11a in a 
binding pose where the sulfone functional group is recognized by the same binding pocket 
(site-1) as T5910047. The PC-Score = ޤ8.9 kcal/mol and is slightly less favorable than that 
for T5910047 (-9.2 kcal/mol). 
Of the three SMAs, 12b scored most favourably in PC-Score ޤNFDOPROeven 
performing better than T5910047 and T6167923.  The docking of 12b is shown in Figure 3e 
& f. As with 11a, this compound favoured binding to site-2, to which T5910047 binds in the 
model, but did not mimic the binding mode of T5910047 to that site.   However, an 
alternative binding pose of 12b to site-1 bound almost as strongly with PC-Score ޤ
kcal/mol and blocked the small pocket recognized by T5910047 in site-1 (Figure 3e).  The 
importance of this pocket as a possible recognition point for inhibitors reflects its peripheral 
location to the BB-loop region of MyD88, which is a conserved region in the TIR domain.  In 
contrast to SMAs 11a and 12b, the best binding pose of SMA 19o had a less effective PC-
Score RIޤNFDOPRO and performed similarly to T5910047.  However, docking suggests 
that 19o bound to site-1 in the model but in an orientation substantially different from that of 
T5910047 (Figure 3g & h).  
Together the docking results indicate that it is possible that the SMAs 11a and 12b might 
interfere with MyD88 function in a manner similar to T5910047 but that SMA 19o might 
behave significantly differently; this is consistent with the inactivity of 19o in cytokine 
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stimulation profile experiments13,16,18. Further experimental evaluation of the actions of 11a 
and 12b on MyD88 signalling was therefore undertaken. 
ES-62 SMAs inhibit MyD88-dependent cell signalling and cytokine production 
The effect of the SMAs in comparison with the T-series  compounds on LPS-induced TLR4-
dependent MyD88 signalling was investigated first using a cell-based reporter assay (SEAP) 
using protocols we described previously29,30,33. A stably co-transfected HEK 293T cell line 
(TLR4-MD2-NF-NB/ SEAP) was employed to measure ligand (LPS)-induced MyD88-
mediated NF-NB driven SEAP reporter activity (Figure 4). Both of the compounds 11a and 
12b inhibited LPS-induced MyD88±mediated SEAP expression in a dose-dependent manner, 
while, consistent with previous functional studies13,16,18 and potentially reflecting the 
modelling data (Figure 3), 19o showed very weak inhibitory action apart from at high 
concentrations. SMAs 11a and 12b were active between 1-10 PM, consistent with our 
previous findings demonstrating their inhibition of TLR4-driven functional responses (IL-6 
release) in mouse bone marrow-derived macrophages at >3 PM13. These current findings 
were supported by analysis of the IC50 values (60 +/- 16 PM and 28 +/- 21 PM, respectively) 
obtained from 3 independent experiments that showed the potency of 11a and 12b to be not 
VLJQLILFDQWO\GLIIHUHQWIURPWKH³EHVW´VHFRQGJHQHUDWLRQFRPSRXQGRIWKH7-series, 
T616792333 (63 +/- 10 PM) but stronger than that of the prototypic T5910047 compound, 
which perhaps consistent with their similar PC-scores, was not significantly different to the 
³LQDFWLYH´(6-62 SMA, 19o (Figure 4).  
Next, we assessed the effect of 11a and 12b, relative to the T series compounds, on LPS-
induced MyD88-driven pro-inflammatory cytokine signalling in primary human peripheral 
blood mononuclear cells (PBMCs) (Figure 5, left-hand panels).  This showed 12b, in 
particular, to be substantially more potent than T6167923, in inhibiting LPS-induced release 
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of IL-1E and IL-6 from PBMCs (Figure 5a & b). Moreover, both 11a and 12b were 
considerably more effective than T6167923 in inhibiting release of TNFD and IFNJ from 
such cultures (Figure 5c & d) and indeed, even 19o proved somewhat active against the 
release of IFNJ: these perhaps unexpected IFNJ data may reflect that release of this cytokine 
can result from both indirect (via IL-12 production) and direct (on NK cells) actions of LPS 
on PBMCs34,35, with the latter possibly explaining the potent activity of all 3 SMAs (1 µM) 
against IFNJ production. These data are reinforced by the IC50 values determined for the ES-
62 SMAs and T series compounds (Figure 5e), where similarly to the SEAP activity, 
cytokine inhibition was achieved at a lower concentration of 12b than of 11a, and also 
relative to the T-series compounds. These results support the proposed MyD88 target 
specificity of the compounds 11a and 12b in inhibiting NF-ț%GULYHQ6($3DFWLYLW\ and 
cytokine release.  
Other receptors besides TLRs signal via MyD88, for example IFNJ and MHC-mediated 
responses also engage this adaptor molecule21-26. Indeed, our previous results demonstrated 
that SEB activates MyD88-mediated pro-inflammatory cytokine signalling via binding to 
MHC class II molecules on primary human monocytes36 and consistent with this, there is a 
decrease in serum levels of such cytokines induced by exposure to SEB in MyD88 gene 
knockout (MyD88-/-) mice 37,38. It should also be borne in mind, however, that SEB may 
impact on PBMCs via TLR2-MyD88 signalling39,40. Nevertheless, to determine whether by 
targeting MyD88, 11a and 12b would also be capable of inhibiting SEB induced pro-
inflammatory cytokine responses, we stimulated primary human PBMCs with SEB in the 
presence of the SMAs (Figure 5, right-hand panels). Dose response analysis again showed 
12b to be the most potent compound by a substantial margin, whilst 11a and T6167923 
generally displayed similar activities. Also, for this stimulus, 19o was the least active 
compound tested and in contrast to what was observed for the LPS cultures, did not show 
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activity against the (much stronger) IFNJ responses elicited by SEB (Figure 5a-d). Moreover, 
the IC50 values (Fig. 5e) showed the relative potencies, apart from those relating to the IFNJ 
responses, to be broadly consistent with the data obtained with LPS stimulation. Collectively, 
as we have previously shown for TLR-MyD88 signalling in mouse BMMs13, these data 
potentially suggest some selectivity amongst the SMAs with respect to the receptor-MyD88 
coupling targeted. 
SMA 12b interacts directly with MyD88 to inhibit its dimerisation and results in MyD88 
downregulation  
To confirm the SMAs functionally reduce MyD88 signalling by directly binding to the TIR 
domain of MyD88, we performed the LPS-induced cell-based SEAP reporter assay after pre-
incubation of the more potent of the two active compounds in this study, SMA 12b (100 
µM), with different amounts of TIR domain protein (1-100 µg). Pre-incubation with TIR 
domain protein was found to block the inhibitory effect of 12b on SEAP expression in a 
dose-dependent manner, as shown by a greater SEAP response when compared to that 
observed following pre-incubation with BSA as a control protein (Figure 6a).  These results 
clearly demonstrate the specificity of SMA 12b in targeting the TIR domain of MyD88 and 
indicate that direct binding of the SMA to the TIR protein reduced the inhibitory effect of the 
compounds on MyD88-signaling. To gauge the quantitative impact of SMA action in binding 
to MyD88, analysis of the effects of 2 independent experiments showed that whilst exposure 
to 12b resulted in an average of 77% inhibition of the LPS response, this was substantially 
reduced by 25 µg TIR (to 48% inhibition) but not BSA (74% inhibition, i.e., comparable to 
the 77% described above). Indeed, it was estimated that each 5-fold increase in TIR 
concentration produced a 14.64% increase in SEAP activity (95% confidence interval 11.647 
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to 17.720 %), whereas essentially no change in activity was observed with BSA protein.  
Regression analysis shows this to be a statistically significant effect (P < 0.05; Figure 6b).  
Finally, as the dimeric form of MyD88 is generally required for signal transduction and pro-
inflammatory cytokine responses25,26, we next determined whether SMA 12b binding to the 
TIR domain of MyD88 is reflected by it preventing homodimerisation of newly synthesized 
MyD88 to inhibit LPS-induced MyD88 mediated signalling for pro-inflammatory responses. 
Specifically, we examined MyD88-deficient HEK 293T cells that were co-transfected with 
plasmids pCMV-HA-MyD88 and MyD88-Flag and 7 h later incubated with LPS in the 
presence of various concentrations of compound 12b. Cell lysates were co-
immunoprecipitated using anti-Flag antibody, and then analysed by SDS-PAGE followed by 
immunoblotting, the latter employing an anti-HA antibody. In addition, after stripping of the 
blot, re-probing using anti-MyD88 antibody was undertaken to validate the identity of the 31 
kDa band as MyD88. As we have shown previously, LPS binding to TLR4 induced a slightly 
higher level of HA-MyD88 and total MyD88 expression29,31,38 in the immune complexes. By 
contrast, in the presence of compound 12b, the levels of newly expressed Flag-MyD88/HA-
MyD88 homodimer were reduced, with maximum inhibition of HA-MyD88 expression being 
observed at between 10 µM and 100 µM. By contrast, no inhibition of MyD88 
homodimerization in terms of HA-MyD88 expression was observed with control compound 
19o at the highest concentration (Figure 7). Although the levels of total MyD88 detected 
were generally not so dramatically inhibited as those of HA-MyD88 (e.g. ~50% versus ~80% 
at 10 µM respectively) due to the anti-MyD88 antibody detecting the presence of monomeric 
Flag-MyD88 in the immune complexes, re-probing with anti-MyD88 antibody provided 
supporting evidence for exposure to compound 12b resulting in inhibition of MyD88 
homodimerisation (Figure 7). In addition, this approach to analysing MyD88 dimerisation 
also indicated that a consequence of its disruption is downregulation of the adaptor molecule 
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as evidenced by the almost complete loss of detection of newly synthesised MyD88 at the 
highest SMA concentration. By contrast but in agreement with our earlier reports 
demonstrating that 19o does not downregulate MyD88 expression13,16,18, the levels of MyD88 
expression were not reduced as indicated by the levels of total MyD88. These data 
demonstrating inhibition of Flag-MyD88 and HA-MyD88 dimerisation and associated 
downregulation by SMA 12b, are consistent with the effects of this ES-62 SMA on SEAP 
reporter expression and cytokine inhibition (Figures 4 and 5). Certainly, inhibition of 
dimerization of the adaptor would be likely to result in reduction in downstream signalling as 
the dimeric form of MyD88 is generally required for signal transduction and pro-
inflammatory cytokine responses25,26 whilst monomeric MyD88 is susceptible to degradation 
via autophagy39.  
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Discussion 
 
 
This study was undertaken to investigate the possibility that SMAs of the immunomodulatory 
protein, ES-62, might owe their activity at least in part to interacting directly with the 
scaffolding protein, MyD88 with consequent inhibition of its dimerisation resulting in our 
previously observed downregulation of MyD88 expression13,16,18. SMAs of ES-62, 
principally those designated 11a and 12b (Figure 1) have been shown to be effective in 
modulating immune responses in cellular studies and in vivo models of disease, in the latter 
case with substantial quantifiable improvement in disease-related metrics9,13-19. The first 
implication of the involvement of MyD88 came from the observation that its levels were 
decreased on treatment with SMAs in studies of a mouse model of CIA13,16. Whilst the loss of 
TLR signalling resulting from downregulation of MyD88 was consistent with the observed 
reduction in cytokine output, there was no evidence from this previous work to suggest that 
the SMAs interacted directly with MyD88.  
Other studies have however, aimed to design molecules that target MyD88 by direct 
interaction, and have shown for example that the dimerisation of MyD88 can be impeded by 
small, synthetic compounds, typically peptides that had been designed to bind to the surface 
of the TIR subunit of the adaptor molecule27. One study that was of particular interest 
involved the virtual screening of 5 million compounds through a molecular model of the TIR 
subunit interface that led to the identification of a significant number of active compounds, 
referred to in this paper as the T-series (Figure 2)33. The molecular model built for the 
discovery of the T-series compounds was also appropriate for the evaluation of the SMAs. 
Three SMAs were chosen, 11a and 12b, which were known to be active in cell-based studies 
and in vivo, and 19o, which exhibited virtually no activity, as a negative control. The docking 
studies carried out with the SMAs using the same protocol as for the discovery of the T-series 
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showed that the two sets of compounds could indeed bind at the same sites as the T-series 
(Figure 3). Of the many potential binding poses, quantitative evaluation of the most tightly 
binding showed that 11a and 12b bound to the same sites as the T-series compounds with 
similar potency. For 11a some poses, although not the tightest binding, had the sulfone 
binding in the same small protein pocket as the sulfonamide in the T-series compound, 
T5910047 (Figure 3d), which was encouraging but not necessarily highly significant due to 
the general inactivity of sulphonamide-based SMAs referred to earlier. On the other hand, 
inactive 19o bound in a different orientation, although with similar calculated affinity. The 
molecular model therefore reproduced the behaviour expected from the known biological 
properties of the SMAs under investigation. 
The two active SMAs, 11a and 12b, were taken forward in cell-based assays to confirm their 
effects on MyD88-dependent signalling as shown by NFN-B driven SEAP activity and 
cytokine release profiles from human cells in comparison with the T-series compounds 
(Figures 4 and 5) and in both sets of experiments the SMAs were found to be as effective or 
better than the T-series compounds. It was also noted that the activity of 11a and 12b was 
similar to that of a previously described MyD88 dimerisation inhibitor known as 4210 
targeting BB-loop in the TIR domain of MyD8830. In the present study, an effect on the 
release of four principal pro-inflammatory cytokines, IFN-J, IL-1E, IL-6, and TNF-Dwas 
observed with respect to the use of both SMAs. With LPS as the stimulator, both SMAs were 
more potent than the T-series compounds and with SEB exposure, inhibition was similar or 
greater than with the T-series compounds: 12b was found to be particularly potent with low 
and submicromolar IC50 values observed. 
The molecular modelling and cytokine production data raised the possibility that treatment of 
cells with SMA 11a or 12b might have a direct effect on MyD88 and clear evidence for the 
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engagement of 12b with MyD88 was obtained, by the inhibitory effect of added recombinant 
TIR domain on the SMAs ability to inhibit SEAP activity in the reporter assay. Although 11a 
was generally found to be 5±10 fold less potent than 12b in the cytokine release assays 
(Figure 5), it is reasonable to infer that overall it operates in a similar manner to 12b in 
binding to the MyD88 TIR domain, bearing in mind the overall likeness of the two SMAs¶ 
behaviour in the range of molecular modelling and cellular evaluations reported above.  
Recruitment of MyD88 as a dimer is a prerequisite for MyD88-mediated downstream 
signalling for pro-inflammatory responses and consistent with this, a reduction in 
homodimerisation accompanied by downregulation of MyD88 expression was observed 
when adopting a co-precipitation/Western blotting approach with cells transfected with 
MyD88 carrying two distinct labels. Our data are consistent with a recent independent report 
that the cellular consequence of blocking MyD88 dimerisation is that it becomes vulnerable 
to autophagolysosomal degradation39 and now provide a mechanism for our previous 
observations that the protection against CIA afforded by SMAs 11a and 12b is associated 
with downregulation of MyD8813,16. Importantly, this mechanism also resonates with our 
recent studies demonstrating that ES-62 harnesses the homeostatic and selective 
autophagolysosomal degradation of MyD88 and other TLR adaptor/transducers like Traf6 
and PKCG to limit pro-inflammatory responses of dendritic cells40,41.   
The identification of MyD88 as a target of the SMAs 11a and 12b, and by analogy other 
active compounds in the class14, is important for their potential development as therapeutic 
agents in inflammatory and autoimmune diseases. Certainly, our earlier studies with T-series 
inhibitors, as well as with a BB-loop mimetic, designed by a structure based approach to 
target the MyD88 TIR domain and tested by in vitro SEAP based reporter assays30,31,33,38 
demonstrated therapeutic efficacy against toxic shock-induced death when tested in a mouse 
model of SEB intoxication. Thus, the SEAP reporter used in this study in evaluating the 
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functional relevance provides biological significance of the results of 11a and 12b. It is also 
worth emphasising that the in vivo effects of the SMAs are to modulate the relevant 
downstream signalling pathways and not to block them as a kinase inhibitor would. It could 
be argued that modulation is an inherently safer therapeutic strategy than gross inhibition 
since its aim is to restore the natural balance in the context of the relevant biological system. 
The lack of toxicity observed with the SMAs in the now substantial range of in vivo models 
studied9,13,15-19 is consistent with this principle. This in turn suggests that it would be prudent 
in cases of disease of immunological imbalance such as the autoimmune conditions, as 
opposed to infectious diseases in which killing the infecting organism is the therapeutic aim, 
to accept a broader drug discovery paradigm than the traditional one of single compound-
single target-single effect, a paradigm that is rarely met completely by drugs in the clinic in 
any case. 
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Materials and Methods  
Reagents  
ES-62 SMAs 11a, 12b and 19o were prepared as described previously13. T910047, T6167923 
and T5996207 were purchased from Enamine, Ltd (La Jolla, CA).  Staphylococcal 
enterotoxin B (SEB) - endotoxin-free and prepared under GMP conditions -was obtained 
from Porton Down, Inc. (Salisbury, UK) and stored at -50oC. Escherichia coli (ssp. 055:B5) 
lipopolysaccharide (LPS) was from Sigma-Aldrich (St. Louis, MO). The multi-spot array 
ultrasensitive cytokine assay kit was purchased from Meso Scale Discovery (MSD; 
Gaithersburg, MD). Ficoll-Hypaque was purchased from GE Healthcare Biosciences 
(Piscataway, NJ), pooled human AB sera were obtained from Pel-Freez (Brown Deer, WI) 
and the anti-MyD88 antibody was obtained from AnaSpec, Inc. (San Jose, CA).  The 
recombinant MyD88 TIR domain (157-296) protein was expressed in E. coli and purified as 
described in our earlier report33. The stably-transfected HEK 293 TLR4-MD2-NF-kB-
SEAPorter cell line was purchased from Imgenex (San Diego, CA) whilst plasmids 12287 
(pCMV-HA-MyD88) and 13093 (MyD88-Flag) were obtained through an MTA agreement 
with Addgene (Cambridge, MA).  The transfection reagent lipofectamine was from 
Invitrogen (Carlsbad, CA). 
Molecular modelling 
The computational molecular docking methodology applied in this study is slightly different 
from earlier published work33, which was focused on large-scale screening of commercially-
available compounds.  Here, molecular docking simulations are applied to evaluate SMA 
compounds as potential binders to the protein MyD88.  Molecular docking calculations were 
conducted by using the program AutoDock Vina42. The human MyD88 protein was taken 
from the NMR structure listed as 2Z5V in the PDB43 and modelled as a rigid-body target in 
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docking.  For each modeled compound, a docking dataset of 2000 binding poses to MyD88 
were extracted from the simulation generating roughly 2M sampled conformations.   The 
modeling protocol of defining atomic charges and docking parameters was identical to our 
previous work33.   
To help detect native-like binding poses from decoys and provide a relative ranking of 
compounds, two scoring functions were applied.  The first scoring function is that built into 
the AutoDock Vina molecular docking program.  The function (denoted as the free-energy 
SRWHQWLDOGLIIHUHQFHǻG) contains electrostatic interactions through the hydrophobic and the 
hydrogen bonding terms in addition to a solvation/desolvation contribution. The second 
scoring function applied is the knowledge-based function DSX44.  Our implementation of 
DSX is an approach of computing a per-contact score (designated as PC-Score) and is 
formulated as weighted field energy divided by the number atom-atom interactions between a 
ligand and MyD88 (computed within a distance of 6 Å).  In contrast to the Vina scoring 
function, PC-Score yields greater weight to protein-ligand interactions rather than the 
thermodynamic cycle of complex formation.   
Cell Assays 
 Peripheral blood mononuclear cells (PBMCs) were obtained by consent from healthy donors 
in accordance with Institutional Review Board (IRB)-approved research donor protocol 
FY05-05. The minimal risk phlebotomy protocol employed was FDUULHGRXWLQ³DFFRUGDQFH´
with the approved guidelines of Office of Human Use and Ethics (OHU & E). An informed 
written consent was obtained from participants and reviewed by the USAMRIID physician 
(USAMRIID Screening and Eligibility). PBMCs were isolated by standard Ficoll-Hypaque 
density gradient centrifugation and suspended in RPMI 1640 medium as described 
elsewhere31. All of the experimental protocols where PBMCs were used were approved by 
OHU&E and Human Use Committee.  
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Cytokine analysis 
 Purified PBMCs were cultured with LPS (1µg/ml) or SEB (200ng/ml) in the presence of 
varying concentration of SMAs by incubation at (37oC, 5% CO2) for 16 h.  Culture 
supernatants were collected and measured for cytokines using Meso Scale Discovery (MSD) 
multi-spot array ultrasensitive cytokine assay kit DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO as 
described in our previous study33.  
Secreted alkaline phosphatase (SEAP) reporter assays 
 SEAPorterTM HEK 293 cells (TLR4/MD-2/NF-NB/SEAP) were cultured (5×105 
cells/ml/well in 24 well plates) with LPS (1 µg/ml), in the absence or presence of the 
indicated concentrations of test compounds at 37 oC for 16 h.  Following centrifugation to 
remove cell debris, the culture supernatants were collected and the Great EscAPe SEAP 
Assay from Clonetech was used to determine the amount of secreted alkaline phosphatase as 
we described previously33.   
Co-immunoprecipitation and Western blot analysis 
MyD88-deficient HEK 293-I3A cells were co-transfected with plasmids pCMV-HA-MyD88 
and MyD88-Flag and 7 h later, stimulated with LPS in the absence or presence of various 
concentrations of compounds 12b or 19o for 13h. Following washing with ice-cold PBS, 
cells were lysed and cytosolic fractions collected for immunoprecipitation as described 
previously33. Cell extracts (1 mg total proteins) were incubated for 16 h under conditions of 
continuous shaking at 4 °C with 2 µg of mouse anti±Flag M2 antibody conjugated to agarose 
attached to magnetic beads (Sigma-Aldrich).  Following recovery using a magnetic separator, 
agarose bead-bound immunocomplexes were washed three times, eluted in SDS-PAGE 
sample buffer and then separated by SDS-PAGE prior to Western blot analysis33 with anti-
HA antibody followed by stripping the gel and reprobing with anti-MyD88.  
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Statistical analysis 
As indicated, data were analysed by 2-way or 1-DQRYDZLWK%RQIHUURQL¶VSRVW-test. 
The log-log linear regression model fit was utilized to the data relating SEAP activity to TIR 
concentration is fit as shown below in equation 1: 
 ܧݍݑܽݐ݅݋݊ ?ǣܮ݋݃ ൬ ܵܧܣܲܣܿݐ݅ݒ݅ݐݕܣܿݐ݅ݒ݅ݐ݋݂ݏ ?݅݊ܦܯܱܵ൰ ൌ ߚܮ݋݃ሺሾܶܫܴሿሻ ൅ ߙ 
Analysis was carried out in SAS version 9.4 SAS proc MIXED. 
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Figure Legends 
 
Figure 1: SMAs of ES-62 investigated in this work. 
Figure 2: Compounds derived from in silico screening using the MyD88 dimerisation model. 
Figure 3: Molecular docking results for T5910047 and SMAs 11a, 12b and 19o.  The protein 
target MyD88 is illustrated as a molecular surface (coloured tan) with distinct binding regions 
annotated as site 1, site 2 and site 3. Docked molecules are illustrated as sticks with oxygen 
atoms coloured red, nitrogen coloured blue and sulphur coloured yellow.  (a) Two distinct 
binding poses for T5910047 where binding to site-1 is coloured light magenta and to site-2 is 
coloured cyan; (b-d) molecular docking of 11a (coloured pink); (e, f) Docking of 12b 
(coloured pink); and (g, h) docking of 19o (coloured pink).  Docking scores are given by 
9LQDǻG and PC-Score (see text). 
Figure 4. Inhibition of LPS-induced MyD88-mediated SEAP response by ES-62-SMAs. 
SMAs of ES-62 were tested in parallel with the indicated MyD88 T-series inhibitors33 for 
their effects on  MyD88-signalling by monitoring LPS-induced, NF-NB-dependent SEAP 
activity.  Briefly, the stably-transfected HEK 293T cell line (TLR4-MD2-NF-NB-SEAP) was 
stimulated using LPS and treated with various concentrations of the indicated compounds (1-
250 µM).  (a) SEAP activity was determined in culture supernatants and data are presented as 
the mean ± SD values collated from 3 independent experiments, n=9 unless otherwise 
indicated. Statistical analysis was by 2-way ANOVA ZLWK%RQIHUURQL¶VPXOWLSOHFRPSDULVRQ
post-test showing that at: 10 µM, *p<0.05 for  T6167923 and 11a v 19o,  ***p<0.001 
for T6167923 v 12b, 11a v 12b and 12b v 19o; 50 µM (n=6), **p<0.01 for T6167923 v 12b 
and 19o  and  ***p<0.001 for 11a and 12b v 19o; 100 µM (n=3), **p<0.01 for 12b v 19o; 
125 µM (n=6),  ***p<0.001 for each of 11a, 12b and T6167923 v 19o and for 250µM, 
*p<0.05 for T6167923 v 19o and ***p<0.001 for 11a and 12b v 19o. (b) IC50 values were 
 29 
obtained using program Origin pro 7.530,33 and represent the concentration required for 
inhibition of SEAP activity by 50% relative to the control. Again, data are the mean values ± 
SEM from three independent experiments, where *p<0.05, **p<0.01 and ***p<0.001 for the 
various compounds versus T5910047 (blue) or 19o (green) as indicated. 
Figure 5. Inhibition of LPS- or SEB-stimulated cytokine production of human PBMCs by 
SMAs of ES-62. PBMCs (1×106) from normal donors were cultured for 20 h with LPS 
(1µg/ml; left panels) or SEB (200 ng/ml; right panels) with or without the indicated inhibitors 
(1-250 µM). The culture supernatants were collected and measured (in duplicate) for IL-ȕ
(a), IL-E71)ĮFDQG,)NJ(d) production by MSD assay42-44 and the data are presented 
as the means ± SD of duplicate samples (n=4) from two independent experiments. 
Differential efficacy amongst the compounds was revealed by 2-way ANOVA, which for 
clarity is shown here (*p<0.05, **p<0.01 and ***p<0.001) without the dose-by dose post-test 
analysis: thus, for IL-1E, all treatments were significantly different from each other at *** for 
both LPS- and SEB-stimulated responses; IL-6: LPS, T5910047 vs 11a *, T5910047 vs 19o 
**, T5910047 vs 12b and 11a vs12b/19o and 12b vs 19o all ***; SEB, T5910047 was not 
significantly different from 11a but all other comparisons were ***; TNFD: LPS, apart from 
T5910047 vs 19o, which was non-significant, all other comparisons were significant at ***; 
SEB, apart from T5910047 vs 11a, which was non-significant, all other comparisons were 
significant at ***; IFNNJ apart from LPS,T5910047 v 19o, all comparisons were significant 
at ***.  IC50 values (e) were determined as the concentration of compound required to induce 
50% inhibition of cytokine production relative to the control cells from the plotting of dose 
response curves using a scatter plot followed by a sigmoidal curve fit. 
Figure 6. MyD88 TIR-domain validation of the target specificity of compound 12b. To 
determine whether SMA 12b inhibits MyD88-signaling by direct binding to the TIR domain, 
the SMA was pre-incubated at room temperature with varying concentrations (1-500 µM) of 
 30 
TIR domain protein (or with BSA as control) for 2h prior to being added to cells for testing 
for SEAP activity as described in Figure 4. Data (a) are presented as mean ±SD SEAP 
response units from triplicate analysis of a single experiment where *p<0.05, **p<0.01 and 
***p<0.001 for conditions of interest versus LPS+12b by 1-way ANOVA and Bonferroni 
post-test and (b) The log-log linear regression model is fitted to the data relating SEAP 
activity to TIR concentration as shown in equation 1 below by analysis carried out in SAS 
version 9.4 SAS proc MIXED. ܧݍݑܽݐ݅݋݊ ?ǣ ׷ ܮ݋݃ ൬ ܵܧܣܲܣܿݐ݅ݒ݅ݐݕܣܿݐ݅ݒ݅ݐ݋݂ݏ ?݅݊ܦܯܱܵ൰ ൌ ߚܮ݋݃ሺሾܶܫܴሿሻ ൅ ߙ 
Figure 7.  Inhibition of MyD88 homodimer formation in the presence of SMA 12b. HEK 
293T cells (TLR4-MD2-NF-NB-SEAP) co-transfected with plasmids MyD88-Flag or pCMV-
HA-MyD88 for 7h were incubated for a further 13 h with LPS in the presence or absence of 
the compound 12b (100 µM to 1 µM) or control compound 19o (100 µM).   Cell lysates were 
immunoprecipitated (IP) using an anti-Flag antibody, and the resultant immune-complexes 
analyzed by Western blotting employing an anti-HA antibody (a). The identity of the 31 kDa 
MyD88 band was validated by re-probing with an anti-MyD88 antibody (b).   
 
 
